Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 278
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I09A9E1DBD5EN
Leaflet:

Download PDF Leaflet

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2017, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 13, 1, 63 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Idiopathic Pulmonary Fibrosis - Overview
Idiopathic Pulmonary Fibrosis - Therapeutics Development
Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
Idiopathic Pulmonary Fibrosis - Drug Profiles
Idiopathic Pulmonary Fibrosis - Dormant Projects
Idiopathic Pulmonary Fibrosis - Discontinued Products
Idiopathic Pulmonary Fibrosis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Allinky Biopharma, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by AnaMar AB, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by apceth Biopharma GmbH, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Asahi Kasei Pharma Corp, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by aTyr Pharma Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Biogen Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Bioneer Corp, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Co, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Celgene Corp, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Celldex Therapeutics Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Compugen Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Cynata Therapeutics Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by FibroGen Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by FibroStatin SL, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Galapagos NV, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by GenKyoTex SA, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by GlaxoSmithKline Plc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Global Blood Therapeutics Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by iBio Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Inventiva, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Kadmon Corp LLC, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Kasiak Research Pvt Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Lung Therapeutics Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Merck & Co Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Miragen Therapeutics Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Mission Therapeutics Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by MorphoSys AG, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Novartis AG, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Nuevolution AB, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Nuformix Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Pharmaxis Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Promedior Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by ProMetic Life Sciences Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Pulmatrix Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Re-Pharm Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Redx Pharma Plc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Respira Therapeutics Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Ribomic Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Saje Pharma LLC, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Samumed LLC, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Sanofi, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Sorrento Therapeutics Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by SPR Biosciences LLC, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Therabron Therapeutics Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Unity Biotechnology Inc, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Vicore Pharma AB, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Yuhan Corp, H2 2017
Idiopathic Pulmonary Fibrosis - Pipeline by Zai Lab Ltd, H2 2017
Idiopathic Pulmonary Fibrosis - Dormant Projects, H2 2017
Idiopathic Pulmonary Fibrosis - Dormant Projects, H2 2017 (Contd.1), H2 2017
Idiopathic Pulmonary Fibrosis - Dormant Projects, H2 2017 (Contd.2), H2 2017
Idiopathic Pulmonary Fibrosis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Idiopathic Pulmonary Fibrosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Abeome Corp
AdAlta Ltd
Aeolus Pharmaceuticals Inc
Allinky Biopharma
AnaMar AB
apceth Biopharma GmbH
Asahi Kasei Pharma Corp
aTyr Pharma Inc
Biogen Inc
Bioneer Corp
Bristol-Myers Squibb Co
Celgene Corp
Celldex Therapeutics Inc
Chiesi Farmaceutici SpA
Compugen Ltd
Cynata Therapeutics Ltd
F. Hoffmann-La Roche Ltd
FibroGen Inc
FibroStatin SL
Galapagos NV
GenKyoTex SA
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Global Blood Therapeutics Inc
iBio Inc
Inventiva
Isarna Therapeutics GmbH
Kadmon Corp LLC
Kasiak Research Pvt Ltd
Kyorin Pharmaceutical Co Ltd
Lung Therapeutics Inc
Merck & Co Inc
Miragen Therapeutics Inc
Mission Therapeutics Ltd
MorphoSys AG
Novartis AG
Nuevolution AB
Nuformix Ltd
Pharmaxis Ltd
Promedior Inc
ProMetic Life Sciences Inc
Pulmatrix Inc
Re-Pharm Ltd
Redx Pharma Plc
Respira Therapeutics Inc
Ribomic Inc
Saje Pharma LLC
Samumed LLC
Sanofi
Sorrento Therapeutics Inc
SPR Biosciences LLC
Therabron Therapeutics Inc
Unity Biotechnology Inc
Vicore Pharma AB
Yuhan Corp
Zai Lab Ltd
Skip to top


Pulmonary Fibrosis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 377 pages

Ask Your Question

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: